These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 24275098)
1. Relative bioavailability of a paediatric granule formulation of the HIV integrase inhibitor dolutegravir in healthy adult subjects. Patel P; Song I; Borland J; Chen S; Peppercorn A; Wajima T; Funaki T; Fujita N; Hughes J; Piscitelli S Antivir Ther; 2014; 19(3):229-33. PubMed ID: 24275098 [TBL] [Abstract][Full Text] [Related]
2. Relative Bioavailability of a Dolutegravir Dispersible Tablet and the Effects of Low- and High-Mineral-Content Water on the Tablet in Healthy Adults. Buchanan AM; Holton M; Conn I; Davies M; Choukour M; Wynne BR Clin Pharmacol Drug Dev; 2017 Nov; 6(6):577-583. PubMed ID: 28168828 [TBL] [Abstract][Full Text] [Related]
3. Effect of carbamazepine on dolutegravir pharmacokinetics and dosing recommendation. Song I; Weller S; Patel J; Borland J; Wynne B; Choukour M; Jerva F; Piscitelli S Eur J Clin Pharmacol; 2016 Jun; 72(6):665-70. PubMed ID: 26898568 [TBL] [Abstract][Full Text] [Related]
4. Effect of a single supratherapeutic dose of dolutegravir on cardiac repolarization. Chen S; Min SS; Peppercorn A; Borland J; Lou Y; Song I; Fujiwara T; Piscitelli SC Pharmacotherapy; 2012 Apr; 32(4):333-9. PubMed ID: 22422361 [TBL] [Abstract][Full Text] [Related]
5. Effects of Low- and High-Mineral Content Water on the Relative Bioavailability of a Coformulated Abacavir/Dolutegravir/Lamivudine Dispersible Tablet in Healthy Adults. Singh RP; Shaik JSB; Skoura N; Joshi S; Shreeves T; Casillas L; Buchanan AM J Acquir Immune Defic Syndr; 2018 Dec; 79(5):631-638. PubMed ID: 30239425 [TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of dolutegravir when administered with mineral supplements in healthy adult subjects. Song I; Borland J; Arya N; Wynne B; Piscitelli S J Clin Pharmacol; 2015 May; 55(5):490-6. PubMed ID: 25449994 [TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetics of dolutegravir in HIV-infected treatment-naive patients. Zhang J; Hayes S; Sadler BM; Minto I; Brandt J; Piscitelli S; Min S; Song IH Br J Clin Pharmacol; 2015 Sep; 80(3):502-14. PubMed ID: 25819132 [TBL] [Abstract][Full Text] [Related]
8. A Two-Way Steady-State Pharmacokinetic Interaction Study of Doravirine (MK-1439) and Dolutegravir. Anderson MS; Khalilieh S; Yee KL; Liu R; Fan L; Rizk ML; Shah V; Hussaini A; Song I; Ross LL; Butterton JR Clin Pharmacokinet; 2017 Jun; 56(6):661-669. PubMed ID: 27699622 [TBL] [Abstract][Full Text] [Related]
9. Bioavailability of two oral-tablet and two oral-suspension formulations of naproxen sodium/paracetamol (acetaminophen): single-dose, randomized, open-label, two-period crossover comparisons in healthy Mexican adult subjects. Palma-Aguirre JA; Villalpando-Hernández J; Novoa-Heckel G; Oliva I; Cariño L; López-Bojórquez E; Burke-Fraga V; Namur S; González-de la Parra M Clin Ther; 2009 Feb; 31(2):399-410. PubMed ID: 19302912 [TBL] [Abstract][Full Text] [Related]
10. Simplified dolutegravir dosing for children with HIV weighing 20 kg or more: pharmacokinetic and safety substudies of the multicentre, randomised ODYSSEY trial. Bollen PDJ; Moore CL; Mujuru HA; Makumbi S; Kekitiinwa AR; Kaudha E; Parker A; Musoro G; Nanduudu A; Lugemwa A; Amuge P; Hakim JG; Rojo P; Giaquinto C; Colbers A; Gibb DM; Ford D; Turkova A; Burger DM; Lancet HIV; 2020 Aug; 7(8):e533-e544. PubMed ID: 32763217 [TBL] [Abstract][Full Text] [Related]
11. Bioavailability of two oral suspension and two oral tablet formulations of acyclovir 400 mg: two single-dose, open-label, randomized, two-period crossover comparisons in healthy Mexican adult subjects. Palma-Aguirre JA; Absalón-Reyes JA; Novoa-Heckel G; de Lago A; Oliva I; Rodríguez Z; González-de la Parra M; Burke-Fraga V; Namur S Clin Ther; 2007 Jun; 29(6):1146-52. PubMed ID: 17692728 [TBL] [Abstract][Full Text] [Related]
12. Effect of food on the pharmacokinetics of the integrase inhibitor dolutegravir. Song I; Borland J; Chen S; Patel P; Wajima T; Peppercorn A; Piscitelli SC Antimicrob Agents Chemother; 2012 Mar; 56(3):1627-9. PubMed ID: 22183173 [TBL] [Abstract][Full Text] [Related]
13. Comparative bioavailability and pharmacokinetics of investigational enteric- and film-coated formulations of flurbiprofen 100-mg tablets: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy Pakistani male volunteers. Ahmad M; Pervaiz F Clin Ther; 2010 Mar; 32(3):607-13. PubMed ID: 20399997 [TBL] [Abstract][Full Text] [Related]
14. The relative bioavailability and fasting pharmacokinetics of three formulations of olmesartan medoxomil 20-mg capsules and tablets in healthy Chinese male volunteers: An open-label, randomized-sequence, single-dose, three-way crossover study. Li KY; Liang JP; Hu BQ; Qiu Y; Luo CH; Jiang Y; Lin XP; Yang N Clin Ther; 2010 Aug; 32(9):1674-80. PubMed ID: 20974325 [TBL] [Abstract][Full Text] [Related]
15. No clinically significant pharmacokinetic interactions between dolutegravir and daclatasvir in healthy adult subjects. Ross LL; Song IH; Arya N; Choukour M; Zong J; Huang SP; Eley T; Wynne B; Buchanan AM BMC Infect Dis; 2016 Jul; 16():347. PubMed ID: 27450277 [TBL] [Abstract][Full Text] [Related]
16. Comparison of the pharmacokinetics of ticlopidine between administration of a combined fixed-dose tablet formulation of ticlopidine 250 mg/ginkgo extract 80 mg, and concomitant administration of ticlopidine 250-mg and ginkgo extract 80-mg tablets: an open-label, two-treatment, single-dose, randomized-sequence crossover study in healthy Korean male volunteers. Kim TE; Kim BH; Kim J; Kim KP; Yi S; Shin HS; Lee YO; Lee KH; Shin SG; Jang IJ; Yu KS Clin Ther; 2009 Oct; 31(10):2249-57. PubMed ID: 19922896 [TBL] [Abstract][Full Text] [Related]
17. Dose proportionality and the effects of food on bioavailability of an immediate-release oxycodone hydrochloride tablet designed to discourage tampering and its relative bioavailability compared with a marketed oxycodone tablet under fed conditions: a single-dose, randomized, open-label, 5-way crossover study in healthy volunteers. Bass A; Stark JG; Pixton GC; Sommerville KW; Zamora CA; Leibowitz M; Rolleri R Clin Ther; 2012 Jul; 34(7):1601-12. PubMed ID: 22717418 [TBL] [Abstract][Full Text] [Related]
18. Bioequivalence of a Fixed-Dose Combination Tablet of the Complete Two-Drug Regimen of Dolutegravir and Rilpivirine for Treatment of HIV-1 Infection. Mehta R; Wolstenholme A; Di Lullo K; Fu C; Joshi S; Crauwels H; Givens N; Vanveggel S; Wynne B; Adkison K Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29987139 [TBL] [Abstract][Full Text] [Related]
19. Lack of pharmacokinetic interaction between rilpivirine and integrase inhibitors dolutegravir and GSK1265744. Ford SL; Gould E; Chen S; Margolis D; Spreen W; Crauwels H; Piscitelli S Antimicrob Agents Chemother; 2013 Nov; 57(11):5472-7. PubMed ID: 23979733 [TBL] [Abstract][Full Text] [Related]
20. Dolutegravir plasma concentrations according to companion antiretroviral drug: unwanted drug interaction or desirable boosting effect? Cattaneo D; Minisci D; Cozzi V; Riva A; Meraviglia P; Clementi E; Galli M; Gervasoni C Antivir Ther; 2017; 22(4):353-356. PubMed ID: 28008867 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]